These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34083274)

  • 1. HLA-DR and CD74 Expression and the Immune Microenvironment in Renal Cell Carcinoma.
    Miura Y; Anami T; Yatsuda J; Motoshima T; Oka S; Suyama K; Inoshita N; Kinowaki K; Urakami S; Kamba T; Komohara Y
    Anticancer Res; 2021 Jun; 41(6):2841-2848. PubMed ID: 34083274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host.
    Saito T; Kimura M; Kawasaki T; Sato S; Tomita Y
    Cancer Lett; 1997 May; 115(1):121-7. PubMed ID: 9097987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA class I and II antigens expression in patients with renal cell carcinoma.
    Ozgur BC; Gonenc F; Yazicioglu AH
    Saudi J Kidney Dis Transpl; 2009 Jan; 20(1):97-101. PubMed ID: 19112225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host.
    Saito T; Kimura M; Kawasaki T; Sato S; Tomita Y
    Cancer Lett; 1996 Dec; 109(1-2):15-21. PubMed ID: 9020898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data.
    Brasanac D; Marković-Lipkovski J; Hadzi-Djokić J; Müller GA; Müller CA
    Neoplasma; 1999; 46(3):173-8. PubMed ID: 10613593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of HLA class II antigen-associated invariant chain on renal cell cancer].
    Saito T; Tomita Y; Kimura M; Nishiyama T; Sato S
    Nihon Hinyokika Gakkai Zasshi; 1993 Jun; 84(6):1036-40. PubMed ID: 8345720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the frequencies of HLA-class I and II alleles between German patients with renal cell carcinoma and healthy controls.
    Goebel S; Kehlen A; Bluemke K; Altermann W; Schlaf G; Fischer K; Fornara P; Wullich B; Wach S; Taubert H
    Cancer Immunol Immunother; 2017 May; 66(5):565-571. PubMed ID: 28184970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Major histocompatibility complex class II antigens on renal cell cancer--immunohistochemical study and effect on their expression by interferon].
    Tomita Y
    Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1079-86. PubMed ID: 2120500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas.
    Dengjel J; Nastke MD; Gouttefangeas C; Gitsioudis G; Schoor O; Altenberend F; Müller M; Krämer B; Missiou A; Sauter M; Hennenlotter J; Wernet D; Stenzl A; Rammensee HG; Klingel K; Stevanović S
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4163-70. PubMed ID: 16857787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive intracellular expression of human leukocyte antigen (HLA)-DO and HLA-DR but not HLA-DM in trophoblast cells.
    Ranella A; Vassiliadis S; Mastora C; Valentina M; Dionyssopoulou E; Athanassakis I
    Hum Immunol; 2005 Jan; 66(1):43-55. PubMed ID: 15620461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of HLA-DR and CD74 at the cell surface of antigen-presenting cells by single particle image analysis.
    Karakikes I; Morrison IE; O'Toole P; Metodieva G; Navarrete CV; Gomez J; Miranda-Sayago JM; Cherry RJ; Metodiev M; Fernandez N
    FASEB J; 2012 Dec; 26(12):4886-96. PubMed ID: 22889831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
    Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
    Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments.
    Moldenhauer G; Henne C; Karhausen J; Möller P
    Immunology; 1999 Mar; 96(3):473-84. PubMed ID: 10233730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus.
    Badve S; Deshpande C; Hua Z; Lögdberg L
    J Histochem Cytochem; 2002 Apr; 50(4):473-82. PubMed ID: 11897800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules.
    Wilson KM; Labeta MO; Pawelec G; Fernandez N
    Immunology; 1993 Jun; 79(2):331-5. PubMed ID: 8344710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma.
    Oldford SA; Robb JD; Watson PH; Drover S
    Int J Cancer; 2004 Nov; 112(3):399-406. PubMed ID: 15382064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased HLA-DR antigen-associated invariant chain (CD74) mRNA expression predicts mortality after septic shock.
    Cazalis MA; Friggeri A; Cavé L; Demaret J; Barbalat V; Cerrato E; Lepape A; Pachot A; Monneret G; Venet F
    Crit Care; 2013 Dec; 17(6):R287. PubMed ID: 24321376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.
    Kowalczyk D; Skorupski W; Kwias Z; Nowak J
    Br J Urol; 1997 Oct; 80(4):543-7. PubMed ID: 9352689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.